Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pulmonary embolism: what have we learned since Virchow?: treatment and prevention.

Literature DB >> 12426286

Pulmonary embolism: what have we learned since Virchow?: treatment and prevention.

James E Dalen¹.

Abstract

Entities: Disease

Mesh：

Substances：
Anticoagulants
Heparin

Year: 2002 PMID： 12426286 DOI： 10.1378/chest.122.5.1801

Source DB: PubMed Journal: Chest ISSN： 0012-3692 Impact factor: 9.410

Keyword Cloud
Cited

× No keyword cloud information.

10 in total

1. Tenecteplase in the treatment of acute pulmonary thrombo-embolism.

Authors: J S Bhuvaneswaran; Rajendra Kumar Premchand; S S Iyengar; C B Chabra; T N C Padmanabhan; S K Sharma; Alkesh Jain; S A Pandian; S Rajdev; N Modi; V Kumar
Journal: J Thromb Thrombolysis Date: 2011-05 Impact factor: 2.300

2. Is there still a place for thrombolytic therapy in hemodynamically stable patients with acute pulmonary embolism? No.

Authors: Cecilia Becattini; Giancarlo Agnelli
Journal: Intern Emerg Med Date: 2015-02-12 Impact factor: 3.397

3. Anticoagulant treatment for subsegmental pulmonary embolism.

Authors: Hugo Hb Yoo; Vania Santos Nunes-Nogueira; Paulo J Fortes Villas Boas
Journal: Cochrane Database Syst Rev Date: 2020-02-07

4. Risk stratification in submassive pulmonary embolism via alveolar-arterial oxygen gradient.

Authors: O Ince; N Altintas; S Findik; M Sariaydin
Journal: Hippokratia Date: 2014 Oct-Dec Impact factor: 0.471

5. Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.

Authors: Peter K Schädlich; Michael Kentsch; Manfred Weber; Wolfgang Kämmerer; Josef Georg Brecht; Vijay Nadipelli; Eduard Huppertz
Journal: Pharmacoeconomics Date: 2006 Impact factor: 4.981

10. Length of Stay Comparison between Rivaroxaban and Warfarin in the Treatment of Pulmonary Embolism: Results from a Real-World Observational Cohort Study.

Authors: Kirsten M Roberts; Tamara B Knight; Eimeira Padilla-Tolentino; Manasa Murthy; Evan J Peterson
Journal: Thrombosis Date: 2015-12-31

10 in total

Pulmonary embolism: what have we learned since Virchow?: treatment and prevention.

1. Tenecteplase in the treatment of acute pulmonary thrombo-embolism.

2. Is there still a place for thrombolytic therapy in hemodynamically stable patients with acute pulmonary embolism? No.

3. Anticoagulant treatment for subsegmental pulmonary embolism.

4. Risk stratification in submassive pulmonary embolism via alveolar-arterial oxygen gradient.

5. Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.

6. Detection of acute pulmonary embolism: feasibility of diagnostic accuracy of MRI using a stepwise protocol.

7. Early anticoagulation is associated with reduced mortality for acute pulmonary embolism.

Review 8. Acute pulmonary embolism: risk stratification in the emergency department.

9. Efficacy and safety of tenecteplase in pulmonary embolism.

10. Length of Stay Comparison between Rivaroxaban and Warfarin in the Treatment of Pulmonary Embolism: Results from a Real-World Observational Cohort Study.